Financial News

Recent Quotes
My Watchlist
Indicators
Motherlode Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Corvus Pharma Com (NQ: CRVS )

3.480 USD -0.100 (-2.79%)
Official Closing Price Updated: 7:54 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Corvus Pharma Com

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
38 Stocks Moving In Monday's Mid-Day Session
Gainers My Size, Inc. (NASDAQ: MYSZ) shares gained 75.3 percent to $2.91 on no identifiable news. The Israel-based company ... 
Tags YECO NVTR DQ
From Benzinga
Relative Strength Alert For Corvus Pharmaceuticals
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a... 
Tags Stocks
From Market News Video
Corvus Pharmaceuticals is Now Oversold (CRVS)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a... 
Tags Stocks
From Market News Video
Adding Up The Components: Russell 2000 Could Rise 11%
The financial media loves to get predictions from experts about where they think a given stock market index is headed. Some experts look at technical analysis patterns, others look at valuation... 
Tags ETFs
From ETF Channel
Corvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient Selection
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced updated... 
From GlobeNewswire News Releases
BRIEF-Corvus Pharmaceuticals reports third quarter 2017 financial results
* Corvus Pharmaceuticals reports third quarter 2017 financial results and clinical program update 
Tags companyNews
From Reuters: Company News
Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program Update
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial... 
From GlobeNewswire News Releases
Oversold Conditions For Corvus Pharmaceuticals (CRVS)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a... 
Tags Stocks
From Market News Video
Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will... 
From GlobeNewswire News Releases
BRIEF-Corvus Pharmaceuticals entered into a sales agreement with Cowen and Co LLC??
* Corvus Pharmaceuticals - On September 20, 2017, Corvus Pharmaceuticals, Inc entered into a sales agreement with Cowen and Company, LLC?? 
Tags companyNews
From Reuters: Company News
Corvus Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the... 
From GlobeNewswire News Releases
Playing The US Pharma Space: Buy Portola, Hold Corvus, Sell Teva
Ahead of an expected uptick in news flow next month, Credit Suisse reviewed its ratings and price targets on the shares of several ... 
Tags PTLA JNJ TEVA
From Benzinga
Implied VHT Analyst Target Price: $163
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Corvus Pharmaceuticals to Present at the 2017 Wedbush PacGrow Healthcare Conference
Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the... 
From GlobeNewswire News Releases
Corvus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial... 
From GlobeNewswire News Releases
Benzinga's Top Upgrades, Downgrades For August 3, 2017
Top Upgrades Bank of America upgraded Oshkosh Corp (NYSE: OSK) from Underperform to Neutral. Oshkosh shares rose 5.36 percent ... 
Tags Initiations Initiation Analyst Ratings
From Benzinga
Corvus Pharmaceuticals to Host R&D Day Highlighting Role of Adenosine Pathway in Immuno-Oncology
Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will... 
From GlobeNewswire News Releases
Either Analysts Got The Components Wrong or Russell 2000 Headed 10% Higher
The financial media loves to get predictions from experts about where they think a given stock market index is headed. Some experts look at technical analysis patterns, others look at valuation... 
Tags ETFs
From ETF Channel
BRIEF-Corvus Pharmaceuticals announces interim results from its ongoing Phase 1/1b study
* Announces interim results demonstrating anti-tumor activity of CPI-444 in renal and lung cancer patients resistant or refractory to prior PD-(L)1 treatment 
Tags companyNews
From Reuters: Company News
Corvus Pharmaceuticals Announces Interim Results Demonstrating Anti-Tumor Activity of CPI-444 in Renal and Lung Cancer Patients Resistant or Refractory to Prior PD-(L)1 Treatment
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced interim... 
From GlobeNewswire News Releases
Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 in Renal and Lung Cancer at 2017 ASCO Annual Meeting
Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will... 
From GlobeNewswire News Releases
Corvus Pharmaceuticals and Monash University Enter into Exclusive License Agreement for Novel Immuno-Oncology Program
Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company, announced today that it has licensed global rights to an undisclosed novel immuno-oncology program, which... 
From GlobeNewswire News Releases
The Math Shows VTWV Can Go To $123
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Corvus Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial... 
From GlobeNewswire News Releases
Corvus Pharmaceuticals Expands CPI-444 Clinical Collaboration with Genentech
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it has... 
From GlobeNewswire News Releases
BRIEF-Corvus Pharmaceuticals' CEO Richard Miller's total compensation for 2016 was $7.5 mln - SEC Filing
* Corvus Pharmaceuticals Inc - CEO Richard Miller's total compensation for 2016 was $7.5 million - SEC Filing Source text: [http://bit.ly/2oD5Ko3] Further company coverage: 
Tags companyNews
From Reuters: Company News
Disappointment In Corvus Pharma Understandable, But Selloff May Have Been Overdone
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) nearly half its value Tuesday following the release of interim results of its Phase 1 study of ... 
Tags Mara Goldstein Corvus Pharmaceutical Analyst Ratings
From Benzinga
18 Biggest Mid-Day Gainers For Wednesday
Plug Power Inc (NASDAQ: PLUG) shares surged 64.6 percent to $2.14 following a deal with Amazon.com, Inc. (NASDAQ: AMZN). Plug ... 
Tags GBX Markets PLUG
From Benzinga
Corvus Pharmaceuticals (CRVS) Leaps After Tuesday Climb
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) rose 7.9% to $11.18 after surging 50% on Tuesday. Share volume was 1.1 million, triumphing over an all-day average of 127,000 
From Baystreet.ca RSS Feed
Analysts Expect EQWS To Hit $44
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback